The state of health economics and pharmaceoconomics research in Russia: A systematic review

Journal of Pharmaceutical Health Services Research

Volumn 1, Issue 3, 2010, Pages 113-121

  Gavaza, Paul ^a   Shepherd, Marvin ^a   Shcherbakova, Natasha ^a   Khoza, Star ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Cost; Economic evaluation; Health economics; Pharmacoeconomics; Russia

Indexed keywords

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG RESEARCH; EARLY INTERVENTION; HEALTH ECONOMICS; MEDICAL LITERATURE; PHARMACOECONOMICS; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RUSSIAN FEDERATION; SYSTEMATIC REVIEW;

EID: 79953742387     PISSN: 17598885     EISSN: 17598893     Source Type: Journal    
DOI: 10.1111/j.1759-8893.2010.00023.x     Document Type: Review

References (53)

1. Street A et al. Cost-sharing and pharmaceutical utilisation and expenditure in Russia. J Health Econ 1999; 18: 459-472.
2. Whalen J. Russia's health care is crumbling: dire lack of funds creates sick, dwindling populace and national emergency. The Wall Street Journal 2004; February 13.
3. Hauner D. Benchmarking the Efficiency of Public Expenditure in the Russian Federation. Washington DC: International Monetary Fund, 2007.
4. Long EF et al. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS 2006; 20: 2207-2215.
5. Migliori GB et al. Cost-effectiveness analysis of tuberculosis control policies in Ivanovo Oblast, Russian Federation. Ivanovo Tuberculosis Project Study Group. Bull World Health Organ 1998; 76: 475-483.
6. Winter Y et al. Costs of illness in a Russian cohort of patients with Parkinson's disease. Pharmacoeconomics 2009; 27: 571-584.
7. Yagudina RI et al. Features of pharmacoeconomic methodology in the conditions of public health services of the Russia federation: the review of publications from 1995 to 2007. Farma-koekonomika 2009; 1: 3-6.
8. Lindgren P et al. Cost of Parkinson's disease in Europe. Eur J Neurol 2005; 12: 68-73.
9. Abegunde DO, Stanciole AE. The economic impact of chronic diseases: how do households respond to shocks? Evidence from Russia. Soc Sci Med 2008; 66: 2296-2307.
10. Bobrik A. HIV prevention among drug users in Russian cities: cost-effectiveness analysis. Rossiskii Semenii Vrach 2002; 6: 30-36.
11. Gavaza P et al. The state of health economics and pharmacoeconomics research in Zimbabwe. Curr Ther Res 2008; 69: 268-285.
12. Sullivan SD et al. AMCP Guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefits management organizations. J Manag Care Pharm 2001; 7: 272-282.
13. Zarnke K et al. Cost-benefit analysis in the health care literature: don't judge a study by its label. J Clin Epidemiol 1997; 50: 817-822.
14. Offman J et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm 2003; 9: 53-61.
15. Drummond MF et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 2005.
16. Gavaza P et al. The state of health economic and pharmacoeconomic research in Nigeria: a systematic review. Pharmacoeco-nomics 2010; 28: 1-15.
17. Zaridze D et al. Alcohol and cause-specific mortality in Russia: a retrospective case-control study of 48,557 adult deaths. Lancet 2009; 373: 2201-2214.
18. Stickley A, Carlson P. The social and economic determinants of smoking in Moscow, Russia. Scand J Public Health 2009; 37: 632-639.
19. Perlman F et al. An analysis of trends and determinants of health insurance and healthcare utilisation in the Russian population between 2000 and 2004: the 'inverse care law' in action. BMC Health Serv Res 2009; 9: 68.
20. Yablokov AV. Chernobyl's public health consequences. Ann N Y Acad Sci 2009; 118: 132-141.
21. Bobrova N et al. Drinking alcohol surrogates among clients of an alcohol-misuser treatment clinic in novosibirsk, Russia. Subst Use Misuse 2009; 44: 1821-1832.
22. Besstremyannaya G. Micro data assessment of Russian drug benefit monetization. J Health Organ Manag 2009; 23: 465-476.
23. Geltzer A. When the standards aren't standard: evidence-based medicine in the Russian context. Soc Sci Med 2009; 68: 526-532.
24. Bobrova N et al. Challenges in providing drug user treatment services in Russia: providers' views. Subst Use Misuse 2008; 43: 1770-1784.
25. Lettmeier B et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49: 528-536.
26. Larivaara M et al. Between a rock and a hard place: the question of money at St. Petersburg women's clinics. Int J Health Serv 2008; 38: 357-377.
27. Sarang A et al. Access to syringes in three Russian cities: implications for syringe distribution and coverage. Int J Drug Policy 2008; 19 (Suppl. 1): S25-S36.
28. Goryachkina K et al. Quality use of medicines: a new method of combining antibiotic consumption and sensitivity data - application in a Russian hospital. Pharmacoepidemiol Drug Saf 2008; 17: 636-644.
29. Bye SM, Manankov A. Telemedicine in practice in Arkhangelsk region, Russia: from a blank page to routine operation. Int J Circumpolar Health 2007; 66: 335-350.
30. Tkatchenko-Schmidt E et al. Prevention of HIV/AIDS among injecting drug users in Russia: opportunities and barriers to scaling-up of harm reduction programmes. Health Policy 2008; 85: 162-171.
31. Marquez P et al. Adult health in the Russian Federation: more than just a health problem. Health Aff (Millwood) 2007; 26: 1040-1051.
32. Southwick KL et al. Barriers to prenatal care and poor pregnancy outcomes among women with syphilis in the Russian Federation. Int J STD AIDS 2007; 18: 392-395.
33. Syrjanen S et al. Human papillomavirus testing and conventional pap smear cytology as optional screening tools of women at different risks for cervical cancer in the countries of the former soviet union. J Low Genit Tract Dis 2002; 6: 97-110.
34. Floyd K et al. Health-systems efficiency in the Russian Federation: tuberculosis control. Bull World Health Organ 2006; 84: 43-51.
35. Wordsworth S et al. Collecting unit cost data in multicentre studies: creating comparable methods. Eur J Health Econ 2005; 6: 38-44.
36. McDaid D et al. Health system factors impacting on delivery of mental health services in Russia: multi-methods study. Health Policy 2006; 79: 144-152.
37. Abegunde DO et al. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007; 370: 1929-1938.
38. Renton A et al. A trial of the validity of genital smears and cultures with gonococcal vaccine provocation in diagnosing genital gonorrhoea in women. Int J Std Aids 2009; 20: 24-29.
39. Lane S et al. An international observational prospective study to determine the cost of asthma exacerbations (COAX). Respir Med 2006; 100: 434-450.
40. Bloom DE, Malaney PN. Macroeconomic consequences of the Russian mortality crisis. World Devel 1998; 26: 2073-2085.
41. Twigg JL. The cost of illness, disability, and premature mortality to Russia's economy. Eurasian Geogr Econ 2005; 46: 495-524.
42. Simon GE et al. Course of depression, health services costs, and work productivity in an international primary care study. Gen Hosp Psychiatry 2002; 24: 328-335.
43. Marseille E et al. HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries. BMC Health Serv Res 2007; 7: 108.
44. Tole SP et al. Cost-effectiveness of voluntary HIV screening in Russia. Int J STD AIDS 2009; 20: 46-51.
45. Kourbatova EV et al. Assessment of the routine, occupation-based gonorrhea and syphilis screening program in Moscow, Russia: an analysis of sexually transmitted infection prevalence and cost-effectiveness. Sex Transm Dis 2008; 35: 453-460.
46. Atun RA et al. Costs and outcomes of tuberculosis control in the Russian Federation: retrospective cohort analysis. Health Policy Plan 2006; 21: 353-364.
47. Platonov AE et al. Economic evaluation of Haemophilus influ-enzae type b vaccination in Moscow, Russian Federation. Vaccine 2006; 24: 2367-2376.
48. Starostina EG et al. Effectiveness and cost-benefit analysis of intensive treatment and teaching programmes for type 1 (insulin-dependent) diabetes mellitus in Moscow - blood glucose versus urine glucose self-monitoring. Diabetologia 1994; 37: 170-176.
49. Jacobs B et al. Cost-effectiveness analysis of the Russian treatment scheme for tuberculosis versus short-course chemotherapy: results from Tomsk, Siberia. Int J Tuberc Lung Dis 2002; 6: 396-405.
50. World Health Organization Regional Office for Europe. Report on the Programme on Sexually Transmitted Infections/HIV/AIDS Copenhagen. Denmark: World Health Organization Regional Office for Europe, 2002.
51. Amirkhanian YA et al. HIV risk behaviour patterns, predictors, and sexually transmitted disease prevalence in the social networks of young men who have sex with men in St Petersburg, Russia. Int J STD AIDS 2006; 17: 50-56.
52. Walker D, Fox-Rushby JA. Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. Health Econ 2000; 9: 681-698.
53. Lee KS et al. Introducing economic evaluation as a policy tool in Korea: will decision makers get quality information? A critical review of published Korean economic evaluations. Pharmacoeconomics 2005; 23: 709-721.